810 KAR 8:025. Drug, medication, and substance withdrawal guidelines.

RELATES TO: KRS 230.215, 230.225, 230.240, 230.260, 230.265, 230.290, 230.320, 230.370

STATUTORY AUTHORITY: KRS 230.215(2), 230.225, 230.240(2), 230.260, 230.320, 230.370

CERTIFICATION STATEMENT:

NECESSITY, FUNCTION, AND CONFORMITY: KRS 230.215(2) authorizes the Kentucky Horse Racing Commission to promulgate administrative regulations prescribing conditions under which all legitimate horse racing and wagering thereon is conducted in Kentucky. KRS 230.240(2) requires the commission to promulgate administrative regulations restricting or prohibiting the administration of drugs or stimulants or other improper acts to horses prior to the horse participating in a race. This administrative regulation establishes the withdrawal guidelines for permitted drugs, medications, and substances that may be administered to race horses competing in Kentucky.

Section 1. The Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian.

(1) This administrative regulation shall provide certain mandatory treatment requirements, guidance, and advice on medication withdrawal intervals.

(2)  These withdrawal guidelines regarding furosemide shall not apply to two (2) year-old or stakes horses pursuant to 810 KAR 8:010, Section 6.

(3)

(a) Unless otherwise specified in these withdrawal guidelines, KAR Title 810, or KRS Chapter 230, the following withdrawal guidelines in this section are voluntary and advisory. The guidelines are recommendations based on current scientific knowledge that may change over time.

(b) A licensee may present evidence of full compliance with these guidelines to the commission and the stewards as a mitigating factor to be used in determining violations and penalties.

(c) These withdrawal interval guidelines assume that administration of medications will be performed at doses that are not greater than the manufacturer's maximum recommended dosage, or the dosage recommended in this document. Medications administered at dosages above manufacturer's recommendations, in compounded formulations, or in combination with other medications or administration inside the withdrawal interval may result in test sample concentrations above threshold concentrations that could lead to positive test results and the imposition of penalties.

(d) The time of administration of an orally administered substance, for the purposes of withdrawal interval, shall be considered to be the time of complete ingestion of the medication by the horse via eating or drinking.

(e) For products containing multiple medications, the withdrawal time to be used should be no less than the longest identified for any of the individual constituent substances--even if that substance is not present in the highest concentration in the product.

(f) Brand names of medications, where applicable, are listed in parentheses following the generic name of a drug.

(4)

(a) Withdrawal Guidelines. Furosemide shall be administered pursuant to 810 KAR 8:010.

(b) The following substances may be administered or applied up to the scheduled paddock time of the race in which the horse is to compete:

1. Topical applications, such as liniments, leg paints, salves, and ointments, which may contain antibiotics or DMSO, but do not contain steroids, anesthetics, or any other prohibited substances.

2. The following substances may be administered up to twenty-four (24) hours prior to the scheduled post time of the race in which the horse is to compete as long as their use follows subsection (3) of this section:

a. Antibiotics, except those containing prohibited drugs, such as Procaine;

b. Antiprotozoals, such as ponazuril (Marquis), toltrazuril (Baycox), sulfamethoxazole/pyrimethamine (Daraprim);

c. Antifungal agents, such as Griseofulvin and Ketoconazole;

d. Certain inhalation agents that do not exhibit bronchodilator properties, such as cromolyn sodium (Intal), and acetylcysteine (Mucomyst);

e. Cimetadine (Tagamet), orally at 20 mg/kg twice daily for 7 doses;

f. Electrolytes, Vitamins, and Minerals, via IV, IM or oral administration;

g. Any oral supplements or nutrients not containing drugs;

h. Hyaluronic Acid (Legend), via IV administration;

i. Misoprostol;

j. Non-Androgenic Reproductive Hormones, such as HCG, Regumate and GnRH, in fillies and mares only;

k. Omeprazole (Gastrogard), orally at 2.2 g once daily for 4 days;

l. Polysulfated glycosaminoglycan (Adequan), via IM administration;

m. Proprionibacterium acnes suspension (Eqstim), or comparable immunostimulants, excluding levamisole;

n. Ranitidine (Zantac), orally at 8 mg/kg twice daily for 7 doses; and

o. Sucralfate.

3. Non-steroidal anti-inflammatory drugs (NSAIDS):

a. Elected NSAID: Only one of the following three NSAIDS may be administered up to the manufacturer's maximum labeled dosage until forty-eight (48) hours prior to the scheduled post time of the race in which the horse is to compete, as long as their use follows Section 1(3) of this administrative regulation and the requirements of 810 KAR 8:010.

(i) Phenylbutazone (Butazolidin) 4.4 mg/kg, via IV administration only;

(ii) Flunixin Meglumine (Banamine) 1.1 mg/kg, via IV administration only; and

(iii) Ketoprofen (Ketofen) 2.2 mg/kg, via IV administration only.

b. In accordance with the European Horserace Scientific Liaison Committee, the following withdrawal intervals shall be observed for all NSAIDS, except for those established in subparagraph 3.a. of this paragraph, for administration prior to the scheduled post time of the race in which the horse is to compete, as long as their use follows Section 1(3) of this administrative regulation:

(i) Flunixin Meglumine (Banamine) 1.1 mg/kg, via IV administration: 6-day withdrawal interval;

(ii) Phenylbutazone (Butazolidin) 4.4 mg/kg, via IV administration: 7-day withdrawal interval;

(iii) Ketoprofen (Ketofen) 2.2 mg/kg, via IV administration: 4-day withdrawal interval;

(iv) Diclofenac Sodium Topical (Surpass Cream), via a single, 5-inch application: 7- day withdrawal interval; and

(v) Firocoxib (Equioxx) 0.1 mg/kg, via a single oral or IV dose, repeated daily administration: 15-day withdrawal interval from date of last administration.

(5) The following substances have a forty-eight (48) hour withdrawal guidance prior to the scheduled post time of the race in which the horse is to compete as long as their use follows Section 1(3) of this administrative regulation:

(a) Acepromazine (Promace), via IV administration at 0.05 mg/kg;

(b) Butorphanol (Torbugesic), via IV administration at 0.1 mg/kg;

(c) Cetirizine (Zyrtec), orally at 0.4 mg/kg twice daily for 5 doses; although it is recommended that ivermectin should not be administered within forty-eight (48) hours of a race if horse has been administered cetirizine;

(d) Dantrolene (Dantrium), via oral administration at 500 mg total dose;

(e) Detomidine (Dormosedan), via IV administration at 5 mg single dose;

(f) DMSO via IV, oral, or topical administration up to 60 ml;

(g) Glycopyrrolate (Robinol), via IV administration at 1 mg total dose;

(h) Guaifenesin, orally at 2 g twice daily for 5 doses;

(i) Methocarbamol (Robaxin-V), via single IV at 15 mg/kg;

(j) Procaine penicillin, via IM administration at 17 mg/kg; and

(k) Xylazine (Rompun), via IV administration at 200 mg single dose.

(6) The following substances shall not be administered within forty-eight (48) hours of a race:

(a) Beta-2 agonists by inhalation, such as terbutaline, salmeterol, and fenoterol;

(b) Ergot alkaloids, such as Ergonovine and Methergine;

(c) Ipratopium;

(d) Isoxsuprine; and

(e) Pentoxyphylline (Trental).

(7) The following substances may be administered up to seventy-two (72) hours prior to the scheduled post time of the race in which the horse is to compete as long as their use follows Section 1(3) of this administrative regulation:

(a) Albuterol (Proventil) via inhalation at 720 mcg;

(b) Dexamethasone (Azium), via oral, IV, IM administration at 0.05 mg/kg. However, if another corticosteroid was administered systemically or intra-articularly, this withdrawal guidance shall not apply and a minimum five (5) day withdrawal is recommended;

(c) Lidocaine, via subcutaneous administration at 200 mg total dose;

(d) Mepivacaine (Carbocaine), via subcutaneous administration at 0.07 mg/kg; and

(e) Romifidine (Sedivet), via IV administration at 50 mg.

(8) The following substances may be administered up to ninety-six (96) hours prior to the scheduled post time of the race in which the horse is to compete as long as their use follows Section 1(3) of this administrative regulation:

(a) Hydroxyzine (Atarax); and

(b) Phenytoin (Dilantin).

(9) Reserpine (Serpasil) may be administered up to seven (7) days prior to the scheduled post time of the race in which the horse is to compete as long as its use follows Section 1(3) of this administrative regulation.

(10) The use of an extra-corporeal shock wave therapy or radial pulse wave therapy machine may be performed until ten (10) days prior to the scheduled post time of the race in which the horse is to compete, as long as its use complies with 810 KAR 8:010.

(11) The following substance may be administered up to twenty-one (21) days prior to the scheduled post time of the race in which the horse is to compete, as long as its use follows Section 1(3) of this administrative regulation, and its use complies with 810 KAR 8:010, Section 10: Clenbuterol (Ventipulmin), orally up to 0.8 mcg/kg twice daily.

(12) Any horse that has been treated with therapeutic medications found in Section 1 of this administrative regulation may, at the trainer's request and expense, and on permission of a commission veterinarian, have samples of blood or urine collected by the commission veterinarian for analysis by the commission laboratory prior to entry to race in the state of Kentucky.

(a) As a condition of this elective testing, the trainer shall be required to disclose the date and time, dose, and route of administration of the substance for which clearance testing is requested.

(b) A report from the commission laboratory of a negative finding in this pre-race, elective testing shall not provide a safe harbor for the owner, trainer, veterinarian, or horse. A report from the commission laboratory of a positive finding in a post-race sample shall be treated as a violation of KAR Title 810, even if there was a negative finding by the commission laboratory in the clearance testing sample.

(13) The following shall have a fourteen (14) day stand down period for intra-articular injection. Any IA corticosteroid injection within fourteen (14) days shall be a violation:

(a) Betamethasone, via IA administration at 9 mg total dose in a single articular space. Withdrawal time should be increased for use of betamethasone products with a ratio of greater than 1:1 betamethasone acetate to betamethasone sodium phosphate. Intramuscular administration is associated with substantially longer withdrawal times.

(b) Isoflupredone (Predef 2x), via IA administration at 20 mg in a single joint space or 10 mg subcutaneous.

(c) Methyprednisolone (Depo-Medrol), via IA administration at a total dose of less than 100 mg in a single articular space. Intramuscular administration is associated with substantially longer withdrawal times and is not recommended, in accordance with the Racing Medication and Testing Consortium. Clearance testing is recommended in blood and urine prior to entry.

(d) Triamcinolone acetonide (Vetalog), via IA administration at 9 mg total dose in a single articular space. Intramuscular administration is associated with substantially longer withdrawal times.

(14) It is recommended that any horses receiving Fluphenazine (Prolixin) receive pre-race clearance testing.

(15) Withdrawal Guidelines Chart:

|  |  |  |  |
| --- | --- | --- | --- |
| Substance | Brand Name | Recommended Minimum Withdrawal | Administration Specifications |
| Acepromazine | PromAce | 48 hours | 0.05 mg/kg via IV administration |
| Acetylcysteine | Mucomyst | 24 hours | Inhalation |
| Albuterol | Proventil | 72 hours | 720 mcg via inhalation |
| Beclomethasone | Beclovent | 24 hours | Inhalation only |
| Butorphanol | Torbugesic | 48 hours | 0.1 mg/kg via IV administration |
| Cetirizine | Zyrtec | 48 hours | 0.4 mg/ml orally twice daily for 5 doses |
| Cimetadine | Tagamet | 24 hours | 20 mg/kg orally twice daily for 7 doses |
| Clenbuterol | Ventipulmin | 21 days | 0.8 mcg/kg orallyPursuant to 810 KAR 8:010, Section 10, clenbuterol shall be prohibited unless the prescription is made for a specific horse based on a specific diagnosis. The veterinarian shall provide a copy of the treatment sheet to the Equine Medical Director or designee for review within twenty-four (24) hours of administration. A horse administered clenbuterol shall be placed on the veterinarian's list for at least twenty-one (21) days after the last administration. The horse shall meet all conditions for removal from the list, including negative blood and urine sampling. |
| Cromolyn sodium | Intal | 24 hours | Inhalation |
| Dantrolene | Dantrium | 48 hours | 500 mg orally |
| Detomidine | Dormosedan | 48 hours | 5 mg via IV administration |
| Dexamethasone | Azium | 72 hours IV PO, with no other corticosteroids administered. 5 days if other corticosteroids have been administered. | IV, PO, IM, pursuant to the European Horserace Scientific Liaison Committee. |
| DMSO |   | 48 hours | Topical, IV, or oral administration up to 60 ml |
| Ergonovine |   | 48 hours | No dose specified |
| Fenoterol |   | 48 hours | Via inhalation, no dose specified |
| Furosemide2-year-olds beginning in 2020Stakes horses beginning in 2021 | Salix | 24 hours | Administration shall be prohibited at less than 24 hours, and limited to a maximum 500 mg single dose via IV administration |
| Furosemide | Salix | 4 hours | 150-500 mg single IV dose administered by KHRC veterinarian. See 810 KAR 8:010, Section 6. |
| Guaifenesin |   | 48 hours | 2 g orally twice daily for 5 doses |
| Glycopyrrolate | Robinol | 48 hours | 1 mg |
| Griseofulvin | Fulvacin | 24 hours | No dose specified |
| Hyaluronic Acid | Legend | 24 hours | IV administration only; no dose specified |
| Hydroxyzine | Atarax | 96 hours | No dose specified |
| Ipratropium |   | 48 hours | Via inhalation, no dose specified |
| Isoxsuprine | Vasodilan | 48 hours | No dose specified |
| Ketoconazole | Nizoral | 24 hours | No dose specified |
| Lidocaine |   | 72 hours | 200 mg total dose SQ |
| Mepivacaine | Carbocaine | 72 hours | 0.07 mg/kg SQ |
| Methocarbamol | Robaxin | 48 hours | 15 mg/kg single IV |
| Methylergonovine | Methergine | 48 hours | No dose specified |
| Misoprostol | Cytotec | 24 hours | No dose specified |
| Omeprazole | Gastrogard | 24 hours | 2.2 g orally once daily for 4 days |
| Omeprazole | Gastrogard | 24 hours | 2.2 g orally once daily for 4 days |
| Pentoxyfylline | Trental | 48 hours | No dose specified |
| Phenytoin | Dilantin | 96 hours | No dose specified |
| Ponazuril/Diclazuril/Sulfadiazine-Pyrimethamine | Marquis/Protazil | 24 hours | Oral |
| Procaine Penicillin |   | 48 hours | 17 mg/kg IMProcaine penicillin treatments shall be reported to the stewards no later than twenty-four (24) hours after the last injection is administered. Horses so treated may be required to be under commission-approved, continuous surveillance for the six-hour interval prior to the post time for the race in which the horse is entered. The owner of the horse shall be responsible for all costs associated with the surveillance. Prospective surveillance arrangements shall be submitted to the stewards no later than close of business on the day of entry. |
| PSGAG | Adequan | 24 hours | Via IM administration |
| Ranitidine | Zantac | 24 hours | 8 mg/kg orally twice daily for 7 doses |
| Reserpine | Serpasil | 7 days | No dose specified |
| Romifidine | Sedivet | 72 hours | 50 mg via IV administration |
| Salmeterol |   | 48 hours | Via inhalation, no dose specified |
| Sucralfate | Carafate | 24 hours | No dose specified |
| Terbutaline |   | 48 hours | No dose specified |
| Xylazine | Rompun | 48 hours | 200 mg via IV administration |

(16) NSAID withdrawal guidelines chart:

|  |  |  |  |
| --- | --- | --- | --- |
| Substance | Brand Name | Recommended Minimum Withdrawal | Administration Specifications |
| Phenylbutazone | Butazolidin | 48 hours—single elected NSAID. If this is not the single elected NSAID, then 7 days, pursuant to the European Horserace Scientific Liaison Committee. | 4.4 mg/kg via IV administration |
| Flunixin | Banamine | 48 hours—single elected NSAID. If this is not the single elected NSAID, then 6 days, pursuant to the European Horserace Scientific Liaison Committee. | 1.1 mg/kg via IV administration |
| Ketoprofen | Ketofen | 48 hours—single elected NSAID, If this is not the single elected NSAID, then 4 days, pursuant to the European Horserace Scientific Liaison Committee. | 2.2 mg/kg via IV administration |
| Diclofenac | Surpass | 7 days, pursuant to the European Horserace Scientific Liaison Committee. | 5 inch ribbon of Surpass every 12 hours to one site |
| Firocoxib | Equioxx | 15 days, pursuant to the European Horserace Scientific Liaison Committee. | 0.1 mg/kg once daily for 4 days |

(17) Miscellaneous withdrawal guidelines chart:

|  |  |  |  |
| --- | --- | --- | --- |
| Substance | Brand Name | Recommended Minimum Withdrawal | Administration Specifications |
| Anthemintics (except thiazide products |   | 72 hours |   |
| Non-androgenic reproductive hormones | Including HCG, Regumate, GnRH, in fillies and mares only | 24 hours |   |
| Proprionibacterium acnes suspension or comparable immunostimulants |   | 24 hours |   |
| Electrolytes, vitamins, minerals |   | 24 hours | Via IV or IM administration |
| Antibiotics |   | 24 hours |   |
| Any injectable other than furosemide |   | 24 hours | 810 KAR 8:010 specifically prohibits any injections at less than 24 hours to post time for any substance. |
| Intra-articular injections, other than corticosteroids |   | 72 hours |   |

Section 2.

(1) Available Threshold Levels Associated to KHRC Withdrawal Guidelines:

(2) All other NSAIDs not listed on the withdrawal guidelines shall have a threshold set at limit of detection in serum or plasma.

(47 Ky.R. 2188; 48 Ky.R. 35; eff. 10-5-2021; 47 Ky.R. 2188; 48 Ky.R. 35, 1933; eff. 5-31-2022.)